ArticleScientific reports2026
Surveillance of epidemiological characteristics and temporal trends in antimicrobial resistance of Haemophilus influenzae in pediatric lower respiratory tract infections (2021-2024).
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study investigated the clinical characteristics of Haemophilus influenzae (Hi) infections in the lower respiratory tract of pediatric patients in the southwestern Shandong Province, China, aiming to improve early diagnosis and guide clinical management. This retrospective cohort study analyzed pediatric patients with Hi lower respiratory tract infections in southwestern Shandong Province, China. Clinical isolates were obtained through standardized sputum/bronchoalveolar lavage collection protocols and underwent microbiological identification, antimicrobial susceptibility testing, and β-lactamase production detection. All eligible pediatric patients with microbiologically confirmed lower respiratory tract infections during the study period were included, with no additional selection applied.The epidemiological patterns and clinical characteristics were systematically evaluated using electronic medical record data covering the period from January 2021 to December 2024. During the 4-year monitoring period (2021-2024), Hi was isolated from 1028 cases of lower respiratory tract bacterial infections in children, with an overall detection rate of 13.00%. The highest detection rate was observed in children aged 1-3 years (27.23%) and during the first quarter (17.37%, p < 0.05). Single-pathogen infections predominated (83.95%), while polymicrobial infections (16.05%) mainly involved Staphylococcus aureus and Streptococcus pneumoniae. Levofloxacin showed 100% susceptibility. High susceptibility rates (> 93%) were also observed for ciprofloxacin (99.71%), imipenem (99.51%), meropenem (98.74%), ceftriaxone (94.75%), ceftazidime (94.55%), cefotaxime (94.46%), and chloramphenicol (93.29%). Low susceptibility was observed for sulfamethoxazole-trimethoprim (34.73%). Susceptibility to ampicillin and cefuroxime showed significant downward trends (ampicillin: 10.45% in 2021 to 2.13% in 2024, p < 0.001; cefuroxime: 21.82% in 2021 to 7.18% in 2024, p < 0.001). β-Lactamase was produced by 86.28% of isolates, and BLNAR strains accounted for 7.10%. Decreased sensitivity to ampicillin and cefuroxime was observed, alongside sustained low sensitivity to sulfamethoxazole-trimethoprim. Third-generation cephalosporins, carbapenems, and fluoroquinolones remain highly sensitive in vitro. These findings support avoiding ampicillin and cefuroxime in empirical treatment and underscore the need for ongoing resistance surveillance and optimized pediatric antimicrobial stewardship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.